retatrutide triple agonist glp-1 gip glucagon is a triple-agonist drug targeting GLP-1, GIP, and receptors to suppress appetite and boost thermogenesis. Phase 2 trials reported 24.2% average weight loss and over 80% liver fat reduction, reversing retatrutide triple agonist glp-1 gip

Jul 2020;24(3):e272-e277

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus

*Correspondence: Nunzia Balzano [email protected] These authors have contributed equally to this work and share first authorship These authors have contributed equally to this work and share last authorship This article was submitted to Cardiovascular Therapeutics, a section of the journal Frontiers in Cardiovascular Medicine Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers

Nothing worked long term

Functional variants in the glutathione peroxidase-1 (GPx-1) gene are associated with increased intima-media thickness of carotid arteries and risk of macrovascular diseases in japanese type 2 diabetic patients